NEW YORK (GenomeWeb News) – Pathogenica today announced that it has signed a co-marketing pact with Life Technologies for sequencing-based diagnostic tests targeting hospital-acquired infections.
The exclusive deal covers Europe, the Middle East, and Africa and will combine Pathogenica's DxSeq technology with Life Tech's Ion Torrent PGM platform. The kits will be distributed for research use, the firms said, and are not for use in diagnosing hospital patients.
Cambridge, Mass.-based Pathogenica said that its HAI Biodetection Kit detects more than 12 pathogenic bacteria and 15 resistance gene families in a single assay. Up to 12 samples can be tested per sequencing run, it added, and dozens of samples can be simultaneously tested in one day with results achieved in less than 12 hours.
According to the firms, their combined technologies will not only identify what species are present in a sample but also provide high-resolution sequence data that includes strain identity and resistance genes.
Financial and other terms of the alliance were not disclosed.
The alliance is the second this year between Pathogenica and Life Technologies. In May Life Technologies Japan inked a deal to distribute the HAI Biodetection Kit in Japan on the Ion Torrent platform.